NEW YORK (
) hit a new 52-week high Tuesday as it is currently trading at $21.48, above its previous 52-week high of $21.45 with 38.1 million shares traded as of 2:45 p.m. ET. Average volume has been 47.5 million shares over the past 30 days.
Pfizer has a market cap of $161.66 billion and is part of the
industry. Shares are up 20.7% year to date as of the close of trading on Monday.
Pfizer Inc., a biopharmaceutical company, offers prescription medicines for humans and animals worldwide. The company has a P/E ratio of 16.6, above the average drugs industry P/E ratio of 14.5 and below the S&P 500 P/E ratio of 17.7.
- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter
TheStreet Ratings rates Pfizer as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, attractive valuation levels and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full
52-week high stocks
or get investment ideas from our